Updated on 23 October 2015
The first-in-human study will begin recruiting the first of 12 patients in Q1 2016
Singapore: Australian immuno-oncology company, Minomic International, is set to launch the first human study of its novel monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers.
The company has joined hands with with Macquarie University Hospital (MUH) and Macquarie Medical Imaging (MMI) to examine the use of Minomic's proprietary MIL-38 monoclonal antibody as a new tool to enable better detection and targeted treatment of prostate and other cancers.
This first-in-human study will begin recruiting the first of 12 patients in Q1 2016, with the study expected to run during 2016.
Under study protocols, a team of investigators led by Professors Howard Gurney and David Gillatt from MUH and Dr Kevin Ho-Shon of MMI, will examine a chimeric version of Minomic's MIL-38 antibody conjugated with 67Gallium (MILGa) to image cancer metastases following ethics approval.
Investigators will evaluate the technology for safety, sensitivity and specificity of MILGa in these patients.